Evogene Ltd. (EVGN)
NASDAQ: EVGN · Real-Time Price · USD
1.100
-0.005 (-0.45%)
Jun 6, 2025, 4:00 PM - Market closed

Evogene Statistics

Total Valuation

Evogene has a market cap or net worth of $7.57 million. The enterprise value is $16.95 million.

Market Cap 7.57M
Enterprise Value 16.95M

Important Dates

The last earnings date was Wednesday, May 21, 2025, before market open.

Earnings Date May 21, 2025
Ex-Dividend Date n/a

Share Statistics

Evogene has 6.67 million shares outstanding. The number of shares has increased by 27.71% in one year.

Current Share Class 6.67M
Shares Outstanding 6.67M
Shares Change (YoY) +27.71%
Shares Change (QoQ) +0.04%
Owned by Insiders (%) n/a
Owned by Institutions (%) n/a
Float 6.59M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 1.12
Forward PS 0.79
PB Ratio 0.61
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 2.50
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 1.06, with a Debt / Equity ratio of 0.21.

Current Ratio 1.06
Quick Ratio 0.84
Debt / Equity 0.21
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -63.07

Financial Efficiency

Return on equity (ROE) is -91.05% and return on invested capital (ROIC) is -68.80%.

Return on Equity (ROE) -91.05%
Return on Assets (ROA) -35.10%
Return on Invested Capital (ROIC) -68.80%
Return on Capital Employed (ROCE) -121.73%
Revenue Per Employee $57,821
Profits Per Employee -$129,991
Employee Count 117
Asset Turnover 0.17
Inventory Turnover 2.78

Taxes

In the past 12 months, Evogene has paid $9,000 in taxes.

Income Tax 9,000
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -84.31% in the last 52 weeks. The beta is 1.37, so Evogene's price volatility has been higher than the market average.

Beta (5Y) 1.37
52-Week Price Change -84.31%
50-Day Moving Average 1.15
200-Day Moving Average 1.80
Relative Strength Index (RSI) 42.46
Average Volume (20 Days) 40,780

Short Selling Information

Short Interest 177,981
Short Previous Month 241,184
Short % of Shares Out 2.67%
Short % of Float n/a
Short Ratio (days to cover) 0.18

Income Statement

In the last 12 months, Evogene had revenue of $6.77 million and -$15.21 million in losses. Loss per share was -$2.48.

Revenue 6.77M
Gross Profit 2.78M
Operating Income -22.77M
Pretax Income -21.46M
Net Income -15.21M
EBITDA -21.15M
EBIT -22.77M
Loss Per Share -$2.48
Full Income Statement

Balance Sheet

The company has $9.85 million in cash and $2.59 million in debt, giving a net cash position of $7.26 million or $1.09 per share.

Cash & Cash Equivalents 9.85M
Total Debt 2.59M
Net Cash 7.26M
Net Cash Per Share $1.09
Equity (Book Value) 12.40M
Book Value Per Share -0.55
Working Capital 902,000
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$20.77 million and capital expenditures -$607,000, giving a free cash flow of -$21.38 million.

Operating Cash Flow -20.77M
Capital Expenditures -607,000
Free Cash Flow -21.38M
FCF Per Share -$3.20
Full Cash Flow Statement

Margins

Gross margin is 41.06%, with operating and profit margins of -336.57% and -224.82%.

Gross Margin 41.06%
Operating Margin -336.57%
Pretax Margin -254.09%
Profit Margin -224.82%
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Evogene does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -27.71%
Shareholder Yield -27.71%
Earnings Yield -200.84%
FCF Yield -282.32%

Analyst Forecast

The average price target for Evogene is $3.50, which is 218.18% higher than the current price. The consensus rating is "Strong Buy".

Price Target $3.50
Price Target Difference 218.18%
Analyst Consensus Strong Buy
Analyst Count 1
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

The last stock split was on July 25, 2024. It was a reverse split with a ratio of 0.1:1.

Last Split Date Jul 25, 2024
Split Type Reverse
Split Ratio 0.1:1

Scores

Evogene has an Altman Z-Score of -12.72. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -12.72
Piotroski F-Score n/a